Gout
Video
Canakinumab cut gout attacks in CANTOS
AMSTERDAM – Post hoc analysis of data collected from the CANTOS trial showed that interleukin-1 blockade with canakinumab halved the rate of gout...
Conference Coverage
EULAR scientific program highlights spectrum of translational research
Latest News
Emergency gout admission increase is ‘call to arms’
LIVERPOOL, ENGLAND – There is a rising rate of emergency gout admissions in England that pharmacist-led clinics could potentially help to reduce...
From the Journals
Allopurinol dose not escalated enough to reduce mortality
A small increase in all-cause mortality was seen with dose escalation, but only 10% of patients exceeded 300 mg allopurinol daily.
Conference Coverage
Febuxostat increases cardiovascular mortality in CARES trial
ORLANDO – FDA-mandated postmarketing safety study raises safety concerns about the gout drug.
News from the FDA/CDC
Health disparities in rural America: Chronic conditions
Black and American Indian/Alaska Native adults most likely to have multiple chronic health conditions.
Conference Coverage
Rheumatology 911: Inside the rheumatologic emergency
SAN DIEGO – Clinical intuition is key to handling medical crises in rheumatology, Dr. Bharat Kumar says.
Conference Coverage
Higher water intake linked to less hyperuricemia in gout
SAN DIEGO – Study provides more evidence to urge patients to hydrate.
News
FDA: Febuxostat may have increased heart-related death risk
The agency reported preliminary findings from a postmarketing safety study started after febuxostat’s approval in 2009.
Conference Coverage
Gout incidence is intertwined with serum urate, but only up to a point
SAN DIEGO – An analysis’ findings “[support] a role for additional factors in the pathogenesis of gout,” according to Nicola Dalbeth, MD.
From the Journals
Febuxostat prevents early gout flares
The study is the first randomized, controlled trial examining the effects of urate-lowering therapy in patients with early gout.